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Human infections by the bacterial pathogen Salmonella enterica represent major disease
burdens worldwide. This highly ubiquitous species consists of more than 2600 different
serovars that can be divided into typhoidal and non-typhoidal Salmonella (NTS) serovars.
Despite their genetic similarity, these two groups elicit very different diseases and
distinct immune responses in humans. Comparative analyses of the genomes of multiple
Salmonella serovars have begun to explain the basis of the variation in disease manifesta-
tions. Recent advances in modeling both enteric fever and intestinal gastroenteritis in mice
will facilitate investigation into both the bacterial- and host-mediated mechanisms involved
in salmonelloses. Understanding the genetic and molecular mechanisms responsible for
differences in disease outcome will augment our understanding of Salmonella pathogen-
esis, host immunity, and the molecular basis of host speciﬁcity. This review outlines the
differences in epidemiology, clinical manifestations, and the human immune response to
typhoidal and NTS infections and summarizes the current thinking onwhy these differences
might exist.
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INTRODUCTION
Salmonella enterica is a highly diverse Gram negative bacte-
rial species containing more than 2600 different serovars dif-
ferentiated by their antigenic presentation. Various serovars
are characterized by their host speciﬁcity or by the clini-
cal syndrome they cause ranging from asymptomatic carriage
to invasive systemic disease. Most S. enterica serovars asso-
ciated with diseases in humans and other warm blooded
animals belong to subspecies I consisting of both typhoidal
and non-typhoidal serovars. Several excellent recent reviews
have highlighted different aspects of invasive salmonellosis (De
Jong et al., 2012; Feasey et al., 2012), discussed the mech-
anisms behind host restriction (Baumler and Fang, 2013),
and detailed salmonelloses in immunocompromised individu-
als (Gordon, 2008; Maclennan, 2014). Here, we will discuss how
typhoidal and non-typhoidal serovars differ in epidemiology,
clinical manifestations, and the immune response they trigger
in humans.
EPIDEMIOLOGY
While many non-typhoidal Salmonella (NTS) serovars such as
Typhimurium and Enteritidis are generalist pathogens with broad
host speciﬁcity, a few S. enterica serovars including Typhi, Sendai,
and Paratyphi A, B, or C are highly adapted to the human host
that is used as their exclusive reservoir. These specialist pathogens,
collectively referred to as typhoidal Salmonella serovars, are the
causative agents of enteric fever (also known as typhoid or paraty-
phoid fever if caused by serovar Typhi or Paratyphi, respectively).
Enteric fever is an invasive, life-threatening, systemic disease with
an estimated global annual burden of over 27 million cases, result-
ing in more than 200,000 deaths (Crump et al., 2004; Buckle
et al., 2012). Enteric fever is endemic in the developing world
in regions that lack clean water and adequate sanitation, facil-
itating the spread of these pathogens via the fecal-oral route. In
recent years, for unknown reasons, the incidence of infectionswith
serovar Paratyphi A is on the rise and in some regions of the globe,
particularly in South–East Asia, this serovar is accountable for up
to 50% of all enteric fever cases (Ochiai et al., 2005; Meltzer and
Schwartz, 2010).
In contrast to typhoid fever which is common in the developing
world, NTS salmonelloses occur worldwide. There are an esti-
mated 93.8 million cases of gastroenteritis due to NTS infection
each year, resulting in approximately 155,000 deaths (Majowicz
et al., 2010). Despite global morbidity,mortality due to NTS infec-
tion is primarily restricted to the developing world. In addition
to contaminated animal-derived food products such as poultry,
eggs, and dairy products, NTS transmission can result from per-
son to person contact or from contact with pets such as cats, dogs,
rodents, reptiles, or amphibians (Hohmann, 2001; Mermin et al.,
2004; Braden, 2006; Haeusler and Curtis, 2013). Another impor-
tant source of infection is consumption of contaminated produce
especially sprouts, tomatoes, fruits, peanuts, and spinach which
have all been associated with recent outbreaks (Berger et al., 2009,
2010; Barton Behravesh et al., 2011; Cavallaro et al., 2011; Jackson
et al., 2013; Bayer et al., 2014).
While normally NTS infections in humans induces gastroen-
teritis, in up to 5% of NTS cases, bacteria cause an inva-
sive, extra-intestinal disease leading to bacteremia and focal
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systemic infections, henceforth referred to as invasive NTS (iNTS;
Mandal and Brennand, 1988). Interestingly, various NTS serovars
(e.g., Typhimurium, Dublin, Choleraesuis, 9,12:l,v:−) tend to
have more potential to cause extraintestinal infections than others.
This implies there is a genetic basis for the emergence iNTS dis-
ease; however, these differences are still not understood (Wilkins
and Roberts, 1988; Marzel et al., 2014). In Sub-Saharan Africa,
iNTS is a major cause of bacteremia in adults and children,
with an estimated annual incidence of 175–388 cases per 100,000
children and 2000–7500 cases per 100,000 HIV-infected adults.
Especially S. Typhimurium sequence type (ST) 313 is associated
with invasive disease. Startlingly, in 20–25% of cases, invasive
infection results in the death of the patients. Other major risk
factors for invasive disease in addition to HIV are co-infection
with malaria and malnutrition (Feasey et al., 2012; Maclennan,
2014).
CLINICAL MANIFESTATIONS
Enteric fever caused by typhoidal serovars differs dramatically
from the gastroenteritis normally associated with NTS. Infec-
tions caused by different typhoidal serovars (e.g., Typhi and
Paratyphi A) cannot be distinguished by clinical presentation
(Meltzer et al., 2005; Patel et al., 2010). The average incubation
period for typhoidal serovars is 14 days with symptoms persist-
ing for up to 3 weeks (Olsen et al., 2003; Wangdi et al., 2012).
Patients most typically present with a gradual onset of sus-
tained fever (39–40◦C). Other frequent symptoms include chills,
abdominal pain, hepatosplenomegaly, rash (rose spots), nau-
sea, anorexia, diarrhea or constipation, headache, and a dry
cough (Stuart and Pullen, 1946). In contrast to enteric fever,
individuals infected with NTS have self-limiting, acute gastroen-
teritis and watery diarrhea. Nausea, vomiting, abdominal pain,
and fever are also common symptoms (McGovern and Slavutin,
1979). With NTS infection, symptoms appear 6–12 h after the
ingestion of the pathogen and clinical symptoms last less than
10 days (Glynn and Palmer, 1992). In the case of iNTS infections,
which are often associated with patients with immunodeﬁciency,
disease more closely resembles enteric fever in that patients
often suffer from high fever, hepatosplenomegaly, and have res-
piratory complications with intestinal symptoms often being
absent.
Both typhoidal and NTS serovars initially adhere to and invade
the intestinal epithelium of the small intestine (Liu et al., 1988).
Unlike NTS infection, infection by typhoidal serovars does not
induce a high inﬂammatory response during the initial invasion
of the intestinal mucosa (Sprinz et al., 1966; Kraus et al., 1999;
Nguyen et al., 2004). Minimal intestinal inﬂammation during
enteric fever is correlated with negligible neutrophil transmi-
gration across the intestinal epithelium in contrast to massive
neutrophil recruitment during intestinal inﬂammation caused by
NTS serovars (McCormick et al., 1995). In immunocompetent
patients, NTS gastroenteritis is self-limiting, with infection being
conﬁned to the terminal ileum and colon. In the case of typhoidal
salmonellae, after passing the intestinal mucosa, bacteria gain
access to underlying lymphoid tissues and multiply intracellularly
within mononuclear phagocytes. Infection quickly becomes sys-
temic with spreading of the pathogen from the intestine to the
mesenteric lymph nodes, liver, spleen, bone marrow, and gallblad-
der. Secondary infection of typhoidal organisms to the small bowel
can occur via secretion in the bile through the enterohepatic cycle
(Gordon, 2008). The absence of robust intestinal inﬂammation
and the lack of neutrophil transmigration are thought to facil-
itate the invasion of typhoidal serovars into the deeper tissues
of the gut and its dissemination to systemic sites (House et al.,
2001).
Interestingly, up to 10% of convalescing, untreated patients
continue to shed S. Typhi in their stool for up to three months
after infection (Parry et al., 2002). One to four percent of individ-
uals infected with S. Typhi become asymptomatic, chronic carriers
that continue to excrete 106–1010 S. Typhi bacteria per gram of
feces for more than 12 months. The role of such chronic carriers
in disease transmission was notoriously demonstrated by the case
of Mary Mallon (Typhoid Mary). During her work at different
households as a cook in the New York City area in the early 20th
century, Mary Mallon infected between 26 and 54 people (Marr,
1999). Another example of an asymptomatic S. Typhi carrier was
“Mr. N” who worked as a cowman and milker in South–East
England and was responsible for a 207 case outbreak of typhoid
fever, which peaked in 1899 but continued until 1909 (Mortimer,
1999). The suspected site of persistence of S. Typhi in carriers
is the gallbladder and gallstones are thought to be an important
risk factor for developing chronic carriage (Levine et al., 1982) as
they are conducive for bioﬁlm formation which protects bacte-
ria from antimicrobial compounds and the host immune system.
Long-term carriage of S. Paratyphi has received much less atten-
tion and is currently less characterized than S. Typhi, but a recent
study in Nepal suggests a similar rate of persistence for serovars
Typhi and Paratyphi A in endemic regions (Khatri et al., 2009;
Dongol et al., 2012).
Long-term carriage of NTS has not been described. How-
ever, even though symptoms usually last only for a few days,
adults excrete Salmonella on average for 1 month after infec-
tion and children under the age of 5 years shed bacteria in their
feces for an average of 7 weeks (Buchwald and Blaser, 1984;
Hohmann, 2001). Interestingly, several studies have shown that
treatment with antibiotics can prolong shedding of NTS bacte-
ria (Aserkoff and Bennett, 1969; Murase et al., 2000), although
these ﬁndings are controversial (Dryden et al., 1996; Hohmann,
2001). In comparison to NTS serovars, the long-term persistence
of typhoidal serovars in humans suggests an enhanced ability of
these pathogens to evade the human immune system (Raffatellu
et al., 2008b).
HUMAN IMMUNE RESPONSE
Infection in humans by NTS serovars induces a strong Th1
response with high levels of IFN-γ, IL-18, IL-12, IL-15, TNF-α,
and IL-10 detected in serum from patients (Mizuno et al., 2003;
Stoycheva and Murdjeva, 2005). Expression of several chemokines
is also induced uponNTS infection,which leads to the recruitment
and activation of macrophages and dendritic cells, and a signif-
icant inﬂux of neutrophils into the intestinal lumen, which is a
hallmark of NTS gastroenteritis. The fact that typhoidal serovars
are not typically associated with acute diarrhea or a strong inﬂux
of neutrophils into the intestinal lumen (Sprinz et al., 1966; Kraus
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et al., 1999; Nguyen et al., 2004) suggests that their initial interac-
tion with the human gut mucosa is less inﬂammatory than that of
NTS serovars.
Recent studies have shown that patients with inherited
deﬁciency of the IL-12/IL-23 system (IL-12p40/IL-12Rβ1) are
highly susceptible to NTS infections, but not to S. Typhi or
S. Paratyphi infections, even though some of these patients
live in endemic areas (MacLennan et al., 2004; Van de Vosse
and Ottenhoff, 2006). These observations support the possi-
bility that different inﬂammatory pathways may be involved in
NTS vs. typhoidal infections including a distinct role for the
IL-12 pathway. This idea is further supported by additional
epidemiological observations indicating that invasive infections
caused by NTS, but not by typhoidal serovars, are often associ-
ated with immunocompromised adults, in particular individuals
infected with HIV (Gordon, 2008; MacLennan and Levine, 2013).
This implies that certain immune responses, malfunctioning
during HIV infection, are required for the immune defense
against systemic infection of NTS, but not against typhoidal
serovars.
The immune response to infection with typhoidal serovars is
complex and involves both humoral and cell-mediated immune
responses (Sztein, 2007). Clinical studies that examined the
immune response of patients infected with S. Typhi showed a
signiﬁcant CD4 and CD8 T cell response to speciﬁc S. Typhi
antigens during typhoid fever, with elevated levels of IFN-γ dur-
ing the acute phase of the disease (Butler et al., 1993; Sheikh
et al., 2011). Transcriptome analysis of peripheral blood mononu-
clear cells (PBMCs) from patients with acute typhoid fever also
demonstrated up-regulation of the genes from the IFN-γ path-
way compared to healthy individuals (Thompson et al., 2009).
Induction of other cytokines in response to S. Typhi infection
include IL-6 and IL-8 which are secreted into the serum dur-
ing the acute phase of typhoid fever (Butler et al., 1993; Keuter
et al., 1994; Gasem et al., 2003). PBMCs from immunized volun-
teers orally vaccinated with an attenuated S. Typhi vaccine secrete
Th1 cytokines including IFN-γ, TNF-α, and IL-10, following sen-
sitization with a number of S. Typhi antigens including ﬂagella
(Wahid et al., 2007). Collectively, these ﬁndings indicate that the
human immune response to S. Typhi infection is predominantly
Th1-associated.
Given that typhoidal serovars do not typically illicit septic
shock, in contrast to many other Gram-negative pathogens that
induce bacteremia and leukopenia (Pohan, 2004; Tsolis et al., 2008;
Gal-Mor et al., 2012), suggests a restrained immune response
mediated by these pathogens in the human host. This view is
consistent with the clinical observation that serum levels of pyro-
genic cytokines IL-1β and TNF-α are relatively low in patients
with typhoid fever compared to the levels found in patients
with sepsis caused by other Gram-negative pathogens. In fact,
IL-1β and TNF-α production by PBMCs has been shown to
be suppressed during the acute phase of typhoid fever (Butler
et al., 1978; Girardin et al., 1988; Keuter et al., 1994; Gasem et al.,
2003).
Despite the increasing prevalence of S. Paratyphi A in endemic
regions, the immune response to S. Paratyphi infection is much
less characterized than the one to S. Typhi. A recent study done
in our group examined the circulating cytokine proﬁle of healthy
Israeli travelers that became infected with S. Paratyphi A during
an outbreak in Nepal. Comparison of 16 cytokines demonstrated
considerable (more than 10-fold) increase in the serum concentra-
tion of IFN-γ, but only a moderate elevation in the concentration
of IL-6, IL-8, IL-10, and TNF-α between convalescence and the
peak time of clinical presentation (Gal-Mor et al., 2012). These
results suggest that the prominent IFN-γ and the moderate TNF-
α, IL-6, and IL-8 responses are common to both typhoid and
paratyphoid fever. Interestingly, no changes in IL-12 serum con-
centrations were detected during the acute phase of the disease
(Gal-Mor et al., 2012), in contrast to its induction seen during
gastroenteritis caused by NTS serovars (Stoycheva and Murdjeva,
2005).
CURRENT THERAPIES AND VACCINES
Antibiotic therapy can prolong the duration of excretion of
NTS and therefore is only recommended for people with severe
illness, invasive disease, or for certain risk groups includ-
ing infants, the elderly, and immunocompromised individu-
als. Enteric fever, on the other hand is always immediately
treated with antibiotics. In the 1990s, physicians moved away
the ﬁrst-line antibiotics chloramphenicol, ampicillin, and cot-
rimoxazole due to widespread resistance amongst S. enterica
serovars. Since then, ﬂuoroquinolones (like ciproﬂoxacin) have
been the primary treatment for salmonelloses, as this class
of drug is particularly effective against intracellular Gram-
negative bacteria. While there is increasing resistance to ﬂu-
oroquinolones, new ﬂuoroquinolones like gatiﬂoxacin hold
promise. Third generation cephalosporins are often the second-
line treatment to treat salmonelloses. In addition, azithromycin
is relatively new drug with activity against both nalidixic acid
resistant and multidrug resistant (MDR) strains (Hohmann, 2001;
Arjyal and Pandit, 2008).
Multidrug-resistance is an increasing problem in S. enterica
serovars. Resistance to multiple antibiotics is especially common
in serovars Typhimurium and Newport and multidrug-resistant
strains are also linked to more severe disease outcome (Krueger
et al., 2014). Notably, many strains of S. Typhimurium Deﬁnitive
Type (DT) 104, which have caused multiple outbreaks since the
1990s, are resistant to ampicillin, chloramphenicol, streptomycin,
sulphonamides, and tetracycline (Mather et al., 2013). Moreover,
new resistant strains of S. enterica are continuously emerging
worldwide. For example, an MDR strain of serovar Infantis now
accounts for up to 35% of the NTS infections in Israel (Gal-Mor
et al., 2010; Aviv et al., 2014). Additional examples are the emer-
gence of resistant strains of serovars Virchow (Weill et al., 2004)
and Heidelberg (Dutil et al., 2010). Similarly, many iNTS strains
are resistant against ampicillin, chloramphenicol, kanamycin,
streptomycin, trimethoprim, and cotrimoxazole (Gordon, 2008;
Kingsley et al., 2009; Msefula et al., 2012). Therefore, there is a
high need to (i) prevent further resistance development through
the prudent use of antibiotics, (ii) improve measures that pre-
vent spread of MDR strains, and (iii) discover new therapies
for salmonelloses. Interestingly, the re-emergence of chloram-
phenicol sensitive strains in areas where resistance was previously
prevalent suggests that cycling or rotation of antibiotics could also
www.frontiersin.org August 2014 | Volume 5 | Article 391 | 3
Gal-Mor et al. Typhoidal and non-tyhoidal Salmonella serovars
be an effective strategy to deal with antibiotic resistance, render-
ing older antibiotics useful once again (Abel Zur Wiesch et al.,
2014).
Three types of vaccines against S. Typhi are currently com-
mercially available, but unfortunately, there is still not a single
licensed vaccine available against S. Paratyphi A, with very lit-
tle, if any, cross-protection provided by the available S. Typhi
vaccines. Vaccination strategies against typhoid fever including
a description of ongoing trials were recently reviewed in detail
(Waddington et al., 2014). The currently licensed S. Typhi vac-
cines include (i) a killed whole cell parenteral vaccine (Engels
et al., 1998), (ii) a live attenuated oral vaccine, designated Ty21a
(Germanier and Fuer, 1975) and, (iii) aVi polysaccharide capsule-
based vaccine (Tacket et al., 1986). There are vaccines against NTS
serovars Enteritidis and Typhimurium which are effective in poul-
try (Desin et al., 2013). However, there are no vaccines available
for NTS in humans or other animal reservoirs such as cattle or
pigs. This represents a signiﬁcant limitation in the existing preven-
tion strategies. Understanding the host speciﬁcity determinants
of S. enterica serovars will aid in future therapeutic and vaccine
development.
WHY DO TYPHOIDAL AND NTS SEROVARS ELICIT SUCH
DIFFERENT HOST IMMUNE RESPONSES?
How do pathogens so similar, belonging to the same subspecies (S.
enterica ssp. I),with>96%DNA sequence identity between shared
genes (McClelland et al., 2001) induce such different clinical man-
ifestations and immune responses in humans? Despite signiﬁcant
advances in the ﬁeld, this question is still far from being answered.
Understanding the genetic andmolecularmechanisms responsible
for differences in disease outcome will aid in our understanding of
Salmonella pathogenesis, host immunity, and the molecular basis
of host speciﬁcity (Table 1).
In vitro tissue culture studies suggest that S. Typhi induces
restrained inﬂammatory responses that do not trigger a pro-
inﬂammatory response via TLR5. Similarly, polarized human
colonic epithelial (T84) cells infected with S. Typhi induce sig-
niﬁcantly lower levels of the neutrophil chemoattractant IL-8
compared to S. Typhimurium infection (Raffatellu et al., 2005).
Raffatellu et al. (2008b) have therefore postulated that S. Typhi
expresses unique virulence factors that allow this pathogen to
overcome the innate immune response in the intestinal mucosa
resulting in the absence of neutrophil inﬁltration and inﬂamma-
tory diarrhea. One of the current hypotheses in the ﬁeld suggests
that the polysaccharide capsular antigenVi in S. Typhi enables this
pathogen to resist phagocytosis and complement killing (Rob-
bins and Robbins, 1984) and masks access to pattern recognition
molecules, resulting in less IL-8production (Raffatellu et al., 2005),
limitedneutrophil inﬂux, and thereby reduced small bowel inﬂam-
mation (Sharma and Qadri, 2004; Wilson et al., 2008). The role of
the Vi antigen regulator TviA, and its putative contribution to S.
Typhi’s ability to evade the immune system have been recently
reviewed (Wangdi et al., 2012). Nevertheless, since the Vi capsule
is largely restricted to serovar Typhi and is absent from serovars
ParatyphiA and Sendai, it cannot explainwhy the clinicalmanifes-
tations of these other typhoidal serovars differ from that of NTS.
Furthermore, the fact that Vi-negative mutants of S. Typhi are still
able to cause a typhoid-like illness in human volunteers (Zhang
et al., 2008), suggests that additional mechanisms are involved
(Figure 1).
Of the approximately 4400 S. Typhi and S. Paratyphi A genes,
about 200 are inactivated or functionally disrupted, while most
of their homologs in S. Typhimurium are intact. Many of the
degraded genes found in the genomes of the typhoid serovars are
involved in motility and chemotaxis or encode for type 3 secretion
systemeffectors, ﬁmbriae, or adhesins that play a role in Salmonella
pathogenicity (McClelland et al., 2004). Furthermore, Salmonella
pathogenicity island (SPI)-7 (encoding the Vi antigen), SPI-15,
SPI-17, and SPI-18 are present in the genome of S. Typhi, but
not in the genome of S. Typhimurium, while SPI-14, present in
S. Typhimurium, is absent from the genome of typhoidal serovars
(Sabbagh et al., 2010). Therefore, it is highly possible that dif-
ferences in virulence and colonization factor composition affect
host–pathogen interactions and disease outcome in humans. This
notion has recently been demonstrated by the expression of the
S. Typhimurium effector, GtgE, in S. Typhi. When secreted into
host cells, GtgE proteolytically degrades Rab29 and confers the
ability of S. Typhi to survive and replicate within macrophages
and in tissues from mice, a normally non-permissive host
(Spano and Galan, 2012).
Recent evidence suggests that NTS serovars have evolved to
ﬂourish in the inﬂamed gut environment and use inﬂamma-
tion to outcompete microbiota (Stecher et al., 2007; Thiennimitr
et al., 2011). It has been proposed that typhoidal strains may
have lost this ability and therefore have evolved to not induce
inﬂammation in the gut but rather thrive systemically. For exam-
ple, a by-product of the acute intestinal inﬂammation triggered
by S. Typhimurium and other NTS serovars is the generation
of the terminal electron acceptors nitrate and tetrathionate in
the lumen of the inﬂamed gut. These compounds can be used
by S. Typhimurium and other NTS serovars to outcompete the
fermenting gut microbes that are unable to utilize these elec-
tron acceptors (Winter et al., 2010). In another recent report,
Nuccio and Baumler (2014) have identiﬁed anetwork of 469 genes
involved in central anaerobic metabolic pathways that are intact in
NTS, but are decayed in the genome of typhoid serovars. Some of
these degraded genes include the ethanolamine utilization path-
way (eut genes) aswell as the vitaminB12 biosynthesis pathway (cbi
and cob genes) required for ethanolamine utilization (Nuccio and
Baumler, 2014). These pathways are hypothesized to enable NTS
to utilize inﬂammation-derived nutrients to outcompete other gut
microbes.
Collectively, a substantial degree of metabolic and virulence
genedegradation exists in the genomesof typhoidal serovarswhich
may explain the restricted host-tropism of these pathogens and
may also provide at least a partial explanation as to why typhoidal
and NTS-infections induce such different clinical presentations
and immune responses in humans.
ANIMAL MODELS
ANIMAL MODELS OF NON-TYPHOIDAL SALMONELLOSES
There are several animal models used to model human gastroen-
teritis caused by NTS. The model which most resembles human
disease is arguably infection of non-human primates (Kent et al.,
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Table 1 | Summary of the differences between NTS and typhoidal serovars associated with disease in humans.
NTS serovars Typhoidal serovars
Serovars Represented by the ubiquitous serovars Typhimurium and
Enteritidis, but ∼1500 other serovars of S. enterica ssp. I
are known
Typhi, Paratyphi, and Sendai
Host range Broad Human-restricted
Epidemiology Worldwide Endemic in developing countries especially
Southeast Asia, Africa, and South America
Reservoirs Farm animals, produce, pets None, human to human transmission
Clinical manifestations Self-limiting gastroenteritis in immunocompetent
individuals (diarrhea, vomiting, cramps)
In immunocompromised patients (including patients with
inherited deﬁciency of the IL-12/IL-23 system and HIV),
disease is associated with invasive extraintestinal
infections
Invasive, systemic disease in immunocompetent
individuals (fever, chills, abdominal pain, rash,
nausea, anorexia, hepatosplenomegaly, diarrhea
or constipation, headache, dry cough)
Disease course Short incubation period (6–24 h)
Brief duration of symptoms (less than 10 days)
Long-term carriage has not been observed
Long incubation period (7–21 days)
Extended duration of symptoms (up to 3 weeks)
One to four percent of infected individuals
become long-term (≥1 year) carriers
Human immune response Robust intestinal inﬂammation, neutrophil recruitment,
Th1 response
Minimal intestinal inﬂammation, leukopenia,
Th1 response
Genetic basis of disease differences
and host speciﬁcity
Low degree of genome degradation
Able to use terminal electron acceptors for anaerobic
respiration in the inﬂamed gut
Unique virulence factors (e.g., ﬁmbriae, SPI-14)
∼5% of the genome is degraded (e.g.,
inactivated metabolic and virulence factor genes)
Unique virulence factors and pathogenicity
islands (e.g., Vi antigen, SPIs 7, 15, 17, and 18)
Vaccination No vaccine available for humans (i) killed whole cell parenteral vaccine, (ii) live
attenuated oral vaccine (Ty21a), (iii) Vi
polysaccharide capsule-based vaccine
Animal models of human disease Streptomycin-pretreated mice
Calves
Non-human primates
Mouse infection with S.Typhimurium
Tlr11−/− mice
Humanized mice
1966; Rout et al., 1974). Rhesus macacques are especially use-
ful for investigating co-infection with simian immunodeﬁciency
virus. For example, infection of SIV-infected macacques with
S. Typhimurium results in a blunted immune response and inva-
sive bacterial disease similar to what is seen in HIV-infected
patients (Raffatellu et al., 2008a). Furthermore, this model is use-
ful for testing the efﬁcacy and safety of potential live Salmonella
vaccines for HIV infected people (Ault et al., 2013). However,
the use of primates is limited by ethical concerns, cost, and
the inability for genetic manipulation. Infection of calves with
S. Typhimurium results in similar pathology to humans. Further-
more, S. Typhimurium is a natural pathogen of cattle and beef is a
common reservoir for human infection (Santos et al., 2001; Costa
et al., 2012). Data from the calf model have provided valuable
insights into host–Salmonella interaction. However, this model
is also restricted by cost and the limited possibility for genetic
manipulation of the host.
Due to the low cost, ease of housing/handling, and genetic
manipulation possible, mouse models are the most widely
used animal models to study bacterial disease. NTS infection
of mice does not mimic gastroenteritis as seen in humans
but results in a typhoid-like systemic disease. However, after
pretreatment of mice with antibiotics such as streptomycin
or kanamycin, S. Typhimurium can overcome the “colo-
nization resistance” presented by the natural microbiota and
thus efﬁciently colonize the cecum and colon. In the now
widely used streptomycin pretreatment model, NTS infection
has been shown to lead to overt inﬂammation characterized
by transmural inﬂammation including epithelial destruction,
inﬁltration of inﬂammatory cells into the mucosa, forma-
tion of crypt abscesses, submucosal edema, and hyperplasia
(Barthel et al., 2003; Hapfelmeier and Hardt, 2005; Sekirov et al.,
2008; Woo et al., 2008). This model is now being exploited
by many research groups to dissect both the bacterial- and
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FIGURE 1 | Molecular bases for differences between typhoidal and
NTS serovars. (A)Typhoidal serovars possess several inactive/degraded
genes compared to NTS serovars such as genes for chemotaxis, adhesion,
and anaerobic metabolism. (B) Both typhoidal and NTS serovars possess
unique virulence factors. For example, some S.Typhi strains express Vi
(Continued)
FIGURE 1 | Continued
capsule that reducesTLR-dependent IL-8 production in the intestinal
mucosa. However, while the Vi capsule plays a role in typhoid fever
manifestation, it is not necessary as it is absent from other typhoidal
serovars and Vi-negative mutants of S.Typhi are still able to cause a
typhoid-like illness in humans. (C) In contrast to typhoidal serovars, NTS
cause severe intestinal inﬂammation. NTS serovars have evolved to utilize
inﬂammation-derived metabolites (e.g., nitrate and tetrathionate), thereby
enhancing their growth in the inﬂamed intestine. Typhoidal serovars have
lost the ability to beneﬁt from inﬂammation-derived metabolites and
disseminate to systemic sites to a much greater extent.
host-mediated mechanisms involved in intestinal inﬂammation
induction by NTS.
ANIMAL MODELS OF ENTERIC FEVER
S. Typhi, S. Paratyphi, and S. Sendai are human-restricted
pathogens. Historically, attempts at eliciting enteric fever in ani-
mal models by infection with S. Typhi have proven to be rather
inadequate. Chimpanzees infected with S. Typhi develop a mild
disease that resembles enteric fever, but only when infected with
a very high dose of 1 × 1011 CFU (Edsall et al., 1960). Another
model for S. Typhi consists of inoculating mice intraperitoneally
with S. Typhi suspended in hog gastric mucin (Pasetti et al.,
2003). However, this model has not been found to correlate well
with human enteric fever and with the expected attenuation of
key Salmonella virulence regulators, such as PhoP (Baker et al.,
1997).
Therefore until recently, due to the lack of suitable ani-
mal models, much of our understanding of enteric fever had
been extrapolated from S. Typhimurium infection in mice. Mice
infected with S. Typhimurium display minimal intestinal pathol-
ogy but become systemically colonized as seen in humans with
enteric fever. This model also allows for investigation of gall-
bladder colonization which is most likely the niche for chronic
S. Typhi carriage in humans (Menendez et al., 2009; Gonzalez-
Escobedo et al., 2013). Susceptible (Slc11a1−/−, also known as
Nramp1) mouse strains have been widely used but also resistant
(Slc11a1+/+) mice have proven useful. Mice with a wild-type
Slc11a1 gene (e.g., 129Sv,DBA) are relatively resistant to highdoses
of S. Typhimurium and have been particularly useful to investi-
gate chronic infection, carriage (Lawley et al., 2006; Monack et al.,
2004), and transmission (Lawley et al., 2008; Gopinath et al., 2012;
Monack, 2012). In general, infection of mice with NTS has pro-
vided invaluable insight into the role of speciﬁc virulence factors in
host invasion, dissemination, and transmission and although the
murine inﬂammatory response to NTS in some ways resembles
the human response to typhoidal serovars (Santos et al., 2001),
conclusions from this model regarding the relevance to human
typhoid disease must be carefully inferred.
In recent years, more sophisticated mouse models have been
developed to study S. Typhi infection. Mathur et al. (2012) have
shown that Salmonella ﬂagellin is recognized in the mouse intes-
tine by Toll-like receptor 11 (TLR11), which is absent from
humans. Tlr11 knockout mice are severely attenuated in innate
epithelial responses to S. Typhi (and S. Typhimurium) and exhibit
signiﬁcant systemic infection following oral administration
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(Mathur et al., 2012; Shi et al., 2012). It will be exciting to see
if this model can also be used for infection with S. Paratyphi.
Another promising novel model is the use of humanized
mice whereby immunodeﬁcient mice (either Rag2−/− Il2rg−/−
or NOD·Cg-Prkdcscid Il2rg−/−) lacking murine T, B, and NK
cells are engrafted with human CD34+ hematopoietic stem
cells (Shultz et al., 2007). These chimeric mice contain human
immune cells including B cells, CD4+ and CD8+ T cells, NK
cells, monocytes, and myeloid and plasmacytoid dendritic cells.
Such humanized mice facilitate S. Typhi replication in the liver,
spleen, and gallbladder and allow long-term persistence to be
modeled (Song et al., 2010; Firoz Mian et al., 2011). In addi-
tion, infection results in a progressive, lethal infection within
two to three days with inﬂammatory cytokine responses resem-
bling human typhoid (Libby et al., 2010). These models suggest
that the presence of human immune cells is prerequisite for sys-
temic infection and in vivo replication of S. Typhi in the mouse.
Although these humanized mice have proven informative to the
study of S. Typhi infection, they are expensive and labor-intensive
models and (so far) not widely used. Another limitation of
such models is that they are subject to considerable inconsis-
tency as a result of the genetic heterogeneity of donors and the
variable degree of engraftment (Libby et al., 2010; Mian et al.,
2011).
PERSPECTIVES
In-depth comparative analyses of the genomes of Salmonella
serovars have begun to explain the basis for the variation
seen in disease manifestations; however, this is still far from
being fully understood. An interesting question in this regard
is whether there is a genetic basis for the emergence of iNTS
strains and why some NTS serovars (e.g., Typhimurium, Dublin,
Choleraesuis, Schwarzengrund) tend to cause more invasive
disease than others. In addition, the mechanisms by which
co-infections (e.g., with Plasmodium falciparum, HIV) con-
tribute to the increased risk of iNTS bacteremia must be fur-
ther investigated. From the perspective of the host response,
one unanswered question is whether there are unique immune
responses to different typhoidal strains (e.g., Typhi vs. Paraty-
phi). And lastly, a fast-developing area of research that has
already had implications on our understanding of salmonelloses
is that of the role of the microbiota in disease outcome (see
review by Santos in this issue). In the case of gastrointestinal
pathogens, the inﬂuence of the host microbiota on pathogen-
esis, host immunity, and disease progression can no longer be
overlooked.
Exploitation of the recent advances in modeling typhoid and
NTS infection in mice is likely to provide novel insights into how
these serovars are able to cause such different diseases. Opportu-
nities remain, however, in the development of “next generation”
humanized mouse models with enhanced human cell engraftment
and function. These models hold much promise as they allow one
to study the pathogenesis of human-restricted serovars, as well as
to test the efﬁcacy of therapeutic agents and experimental vaccines.
Understanding the genetic andmolecularmechanisms responsible
for differences in disease outcome will aid in our understanding
of Salmonella pathogenesis, host immunity, and the molecular
basis of host speciﬁcity. Together, this information may be applied
to control Salmonella infection, with speciﬁc determinants being
targeted for therapeutic and vaccine development.
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